ClinicalTrials.gg
RecruitingNCT07085598Updated Jul 25, 2025

Effect of Vitamin D3 Supplementation on Cardiac Autonomic Nerve Function in Male Epileptic Patients With Hypovitaminosis D

An interventional study of Vitamin D in Epilepsy, sponsored by Bangladesh Medical University. Recruiting at 1 site in Bangladesh. Open to male participants aged 20 Years to 40 Years. Per ClinicalTrials.gov, last updated 2025-07-25.

Sponsored by Bangladesh Medical University · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Primary completion was expected by Oct 2025, 1 year 1 month ago, but the record still lists the study as recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
15
Allocation
Not applicable
Ages
20 Years to 40 Years
Sex
Male
01

Study summary

The goal of this clinical trial is to see the effect of vitamin D3 supplementation on cardiac autonomic nerve function in male epileptic patients with hypovitaminosis D that weather vitamin D improves heart rate variability or not. The main questions it aims to answer are:

  1. Does vitamin D improves cardiac autonomic tone in male epileptic patients?
  2. Does vitamin D improves heart rate variability in male epileptic patients?

It is a self control trial. Participants will:

  1. undergo through baseline HRV testing
  2. start to take vitamin D3 50000 IU once in a week for 8 weeks

b) visit the university after 8 weeks for post interventional HRV testing . Researcher will compare the pre test and post test value of HRV testing.

Read the detailed description

In epilepsy, there is a shifting of autonomic balance toward sympathetic dominance \& heart rate variability (HRV) is reduced which can be detected by interictal heart rate variability (HRV) testing. Patients treated with anti-epileptic drugs (AEDs) are suffered from one of its major adverse effects of vitamin D3 deficiency or hypovitaminosis D due to enzyme inducing effect of AEDs. Vitamin D3 is a neuroprotective hormone that modulates autonomic balance and regulates sympathetic and parasympathetic nervous systems. Vitamin D3 deficiency is also associated with the risk of reduced HRV. Administration of vitamin D3 in vitamin D3 deficient epileptic patients may improve their cardiac autonomic nerve function that can be interpreted by HRV.

02

Conditions studied

  • Epilepsy

Keywords

  • Vitamin D3
  • Hypovitaminosis D
  • HRV
03

In context

Epilepsy

1,850 studies on the registry are indexed under Epilepsy; 418 are open to participants now.

This study's planned enrollment of 15 is below the median of 50 across 1,240 interventional studies indexed under Epilepsy.

Browse Epilepsy studies →

Lead sponsor

Bangladesh Medical University is the lead sponsor of 46 studies on the registry; 28 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 40 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

    • Diagnosed male patients with Epilepsy by neurologist from the OPD of Department of Neurology by taking proper history of at least two unprovoked (or reflex) seizures occuring > 24 hours apart, from patients and eye witnesses.

      • Having hypovitaminosis D (serum vitamin D3 level \<30 ng/ml)
      • Age: 20-40 years.

        • Sex: Male
        • : 18.5-24.9 kg/m2
        • Taking antiepileptic drug for 6 months to 2 years ( Enzyme inducer AEDs, e.g. Carbamazepine, Phenytoin, Phenobarbital)
        • Without medication that affect central nervous system other than antiepileptic drugs (AEDs).

Exclusion criteria

Exclusion Criteria:

    • Epileptic patients taking Sodium valproate, oxcarbazepine, Topiramate, Lamotrigine, Levetiracetam.

      • Patient having absence seizure
      • Alcoholic
      • Smoker
      • Patients taking following drugs will be excluded-

        • Anti-diabetic drugs
        • Antioxidant vitamin supplements
        • Antihypertensive drug
        • Anti-arrhythmic drug
        • Lipid lowering medications
        • Sedatives
      • Patients having known to vitamin D3
      • All patients with the history of or currently suffering from following diseases \& condition will be excluded-

        • Cardiovascular disorders (Myocardial infarction, coronary heart disease, cardiac arrhythmia, CCF)
        • Other neurological disorders (Migraine, stroke)
        • Respiratory disorders (Bronchial asthma, )
        • Renal insufficiency (S. Creatinine > 1.5 mg/dl, Acute or chronic kidney disease)
        • Endocrine disease (Diabetes mellitus, Thyroid disorders- hypothyroidism, hyperthyroidism)
        • Arthritis (rheumatoid arthritis)
        • Liver diseases
        • Neoplastic disease
        • Psychiatric disorder (schizophrenia, bipolar disorder)
        • Current use of iron, zinc, calcium, magnesium and multivitamin supplementation
        • Already performing yoga or breathing exercise
        • Patients with hypercalcemia
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (estimated)

Study arms

  • Experimental
    15 male epileptic patients with hypovitaminosis D

    15 male epileptic patients with hypovitaminosis D will be enrolled. They will be supplemented with Vitamin D orally 50,000 IU/week for 8 weeks

    Dietary Supplement: Vitamin D

Interventions

  • Dietary supplementVitamin D

    15 male epileptic patients with hypovitaminosis D will be enrolled. They will be supplemented with Vitamin D orally 50,000 IU/week for 8 weeks

06

What researchers measure

Primary outcomes

  1. Vitamin D3 supplementation has effects on cardiac autonomic nerve function in male epileptic patients with hypovitaminosis D.

    In epilepsy, cardiac autonomic nerve function is altered which can be measured by heart rate variability test(HRV). HRV is reduced in epilepsy. Vitamin D3 supplementation in patients with epilepsy will improve their cardiac autonomic nerve function which can be detected by measuring various parameters of HRV test such as SDRR, LF(Low frequency).

    Time frame: 8 weeks

07

Study locations

1 of 1 sites recruiting
  • Bangladesh Medical University
    Dhaka, Shahbag 1000, Bangladesh
    Recruiting
    • Dr. Samikha Sarker, MBBS, MD Resident (Phase B) · Contactsamiksha.damc@gmail.com · +88 01774441584
    • Dr. Samikha Sarker, MBBS, MD Resident (Phase B) · Principal investigator
08

References and documents

Publications

  • Teagarden DL, Meador KJ, Loring DW. Low vitamin D levels are common in patients with epilepsy. Epilepsy Res. 2014 Oct;108(8):1352-6. doi: 10.1016/j.eplepsyres.2014.06.008. Epub 2014 Jul 6. PubMed 25060996 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jul 2025; primary completion for Oct 2025, 3 months later.

Of 339 non-industry interventional studies with no phase under Epilepsy, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 77. This study's planned 3 months is below that.

Counting every sponsor, half of 360 studies reached it within 42 months; a quarter within 19 and three quarters within 77.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 12, 2025
First posted
Jul 25, 2025
StartEst.
Jul 2025
Primary completionEst.
Oct 2025
CompletionEst.
Oct 2025
Last update
Jul 25, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 25, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07085598
Lead sponsor
Bangladesh Medical University
Responsible party
Samikha Sarker (Principal Investigator, Bangladesh Medical University) — Principal investigator
First posted
Jul 25, 2025
Start date
Jul 2025 (estimated)
Primary completion
Oct 2025 (estimated)
Completion
Oct 2025 (estimated)
Last update
Jul 25, 2025

Study contacts

Registrar, BMU
Contact
registrar@bsmmu.edu.bd
+88 02 55165708 ext. 94
Dr. Samikha Sarker, MBBS, MD Resident (Phase B)
principal investigator · BMU

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vitamin D

Start the discussion